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The 4th Global Forum on TB Vaccines, convened in Shanghai, China, from 21 e 24 April 2015, brought
together a wide and diverse community involved in tuberculosis vaccine research and development to
discuss the current status of, and future directions for this critical effort. This paper summarizes the
sessions on TB Vaccines in Clinical Development, and Clinical Research: Data and Findings. Summaries of
all sessions from the 4th Global Forum are compiled in a special supplement of Tuberculosis.
[August 2016, Vol 99, Supp S1, S1eS30].
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
At the time of the ﬁrst Global Forum for TB Vaccines, in 2001,
there were not yet any candidate TB vaccines in the worldwide
clinical portfolio [1]. In contrast, in 2015, at the time of the 4th
Global Forum, there were at least 15 candidate TB vaccines and
vaccine combinations being evaluated in clinical trials. This port-
folio contains a variety of vaccine platforms, including recombinant
BCGs, other whole cell mycobacteria or lysates, viral-vectored
vaccines and adjuvanted subunit vaccines (Figure 1), although
these candidates represent only modest diversity of immune
mechanisms with most candidates designed to stimulate primarily
a CD4þ Th1 T-cell response. Most of the 15 candidates in the clinical
pipeline are in relatively early stage evaluation (phases 1 through
2a) or are being used as “tools” to evaluate experimental medicine
hypotheses. One candidate, MVA85A, has progressed to phase 2b
efﬁcacy evaluation [2] but unfortunately did not demonstrate an
increase in efﬁcacy of the BCG-MVA85A prime-boost regimen
compared to BCG alone in South African infants. A correlates of risk
analysis is ongoing on samples from this trial. Another phase 2b
trial, with the GSK candidate M72/AS01E, is underway in Africa [3].
A phase 3 trial is ongoing in China of a therapeutic vaccine, Vac-
cae®, for prevention of TB reactivation disease in those with latentlevard, Rockville, MD 20850,
rg).
Ltd. This is an open access articleMycobacterium tuberculosis (Mtb) infection [4]; results should be
available in the second half of 2016.
The results of theMVA85A phase 2b trial stimulated debate as to
the value of efﬁcacy trials with the current candidate vaccines.
Some maintained that the probability of success for any of the
current candidates is too low, and that the absence of a validated
correlate of protection or predictive animal model makes it difﬁcult
to justify the resources required to conduct large, costly efﬁcacy
trials. Alternatively, however, without any level of human efﬁcacy
data the ﬁeld cannot validate a correlate of protection or a relevant
animal model, nor will it beneﬁt from the iterative learning be-
tween clinical and preclinical studies that can only result when
human efﬁcacy data and animal model data are obtained and
compared on a range of candidates.
Participants also discussed the merits of developing infant
vaccines either to replace or boost BCG versus the development of
vaccines targeted at adolescents and adults. While improved infant
vaccines could provide enhanced safety and/or longer duration of
protection than BCG, effective adolescent/adult vaccines, if deliv-
ered efﬁciently, would provide a more rapid public health impact
because most transmission and the greatest burden of disease are
seen in this latter age group. Ideally, novel TB vaccines will be
developed for both these populations.
2. BCG-based whole cell vaccines
Prof. StefanKaufmann (MaxPlanck Institute for InfectionBiology,
Germany) discussed recombinant BCG (rBCG) vaccine candidates,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Global Clinical Pipeline of TB Vaccine Candidates. The information in Figure 1 is as of December 2015 and is reported by vaccine sponsors. Image courtesy of Aeras.
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infants. Henoted two current approaches to improvingBCGefﬁcacy:
improvement of a beneﬁcial effect or reduction of a potentially
disadvantageous one. The lead rBCG candidate, VPM1002 (BCGur-
eDC::hly), which expresses listeriolysin, was discovered in the
Kaufmann laboratory, licensed to Vakzine Projekt Management
GmbH and sub-licensed to Serum Institute of India [5]. It is designed
to enhance immunogenicity and efﬁcacy by increasing antigen
cross-presentation to MHC Class I-restricted CD8þ T-cells and in-
duction of IL-17 responses. This involves apoptosis and autophagy in
antigen presenting cells. In phase 1/2a studies in adults and infants,
VPM1002 has demonstrated an acceptable safety and immunoge-
nicity proﬁle. A larger phase 2 study that will compare safety and
immunogenicity of VPM1002 and BCG in newborns delivered by
HIV þ mothers has subsequently been initiated in South Africa. A
multicenter therapy trial using VPM1002 to treat bladder cancer has
also been initiated. Additional improvements to VPM1002 continue
to be explored by the Kaufmann laboratory.
Recombinant BCG30 (rBCG30) was designed by the Horwitz
laboratory at UCLA to enhance antigenicity by over-expressing
the 30kd complex of Mtb and completed a ﬁrst-in-human trial
in 2008 [6]. Another rBCG, AERAS-422, was developed to
enhance both antigenicity and immunogenicity via addition of a
mutated perfringolysin from Clostridium perfringens and over-
expression of the Mtb antigens Ag85A, Ag85B and Rv3407. The
development of AERAS-422 was halted, however, by the reac-
tivation of latent Varicella Zoster virus (VZV) infection in two
subjects during the ﬁrst-in-human, phase 1 trial. A third rBCG,
rBCGDzmp1 from the Sander/B€ottger laboratories in Zürich,
Switzerland is designed to reduce immune subversion but has
not yet advanced into clinical testing [7]. In addition to replacing
BCG, vaccine developers are considering rBCGs as a potential BCG
booster, particularly in adolescents and adults, with the aim of
blocking transmission and providing longer duration protection
for this key age group.3. First-in-human phase 1 study results of MTBVAC, a live-
attenuated vaccine from human origin
Dr. Francois Spertini (University of Lausanne, Switzerland) pre-
sented data from a ﬁrst-in-human phase 1 trial in Lausanne,
Switzerland with MTBVAC, an attenuated Mtb strain based on the
deletions in the phoP and fadD26 genes [8]. The trial consisted of
three cohorts, each with three subjects administered BCG and nine
subjects administeredMTBVAC at 5 103, 5 104 or 5 105 colony
forming units (CFU), where the upper dose was chosen to be
equivalent to the licensed BCG dose. Initial analysis of the trial data
demonstrated an acceptable safety proﬁle, and in particular, the
absence of conversion towards positive response to ESAT-6 and
CFP-10 at the end of the trial in all volunteers. Immunogenicity
showed a trend towards a stronger CD4þ T-cell antigen speciﬁc
response, a strong polyfunctional memory response and an
enlargement of the polyfunctional response over time in compar-
ison to BCG. However, the group sizes are still too small to support
statistical analysis, waiting for future phase 2 studies. Memory T-
cells were detectable 210 days post-vaccination; a follow-up in
three to ﬁve years is planned. Globally, MTBVAC was at least as
immunogenic as BCG. These data support advanced clinical
development in high-burden tuberculosis endemic countries.
4. TB vaccine development using recombinant viral vectors
Prof. Helen McShane (University of Oxford, UK) described us-
ing recombinant viral vectored TB vaccines, including MVA85A, as
boosts to BCG. MVA was chosen as the vector for its safety record
and ability to induce both humoral and cellular immune re-
sponses. The phase 2b efﬁcacy study of this vaccine demonstrated
that the modest immune responses induced in South African in-
fants by this vaccine when given as a boost to BCG were not
adequate to provide protection beyond that provided by BCG
alone [2]. The quality and quantity of induced immune responses
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open questions. McShane and colleagues are conducting further
analyses of study samples to identify correlates of risk of TB dis-
ease in this population [9]. These analyses are also being con-
ducted with samples from a recently conducted phase 2 safety
and immunogenicity trial of MVA85A in HIV þ adults in Africa
[10]. McShane discussed three strategies for improving efﬁcacy of
viral-vectored recombinant TB vaccines: 1) combination boosting
strategies, such as an adenovirus-vectored vaccine (induces pri-
marily CD8þ T-cells) followed by an MVA-vectored vaccine (in-
duces primarily CD4þ T-cells), which has been efﬁcacious in a
malaria human challenge model and appears promising for Ebola;
2) inclusion of additional and/or different antigens; and 3) alter-
nate routes of vaccine administration, particularly aerosol de-
livery. McShane's group has conducted a phase 1 study of aerosol
vs. intradermal MVA85A [11]. Aerosol vaccination demonstrated
an acceptable safety proﬁle, with one case of reactivation of latent
VZV infection in a young adult subject who received 108 plaque-
forming units (pfu) of aerosol MVA85A. Aerosol MVA85A also
resulted in robust antigen-speciﬁc CD4þ and CD8þ immune re-
sponses, with greater CD4þ responses in the bronchoalveolar
lavage (BAL) ﬂuid following aerosol compared to intradermal
delivery and comparable systemic CD4þ T-cell responses. Sys-
temic CD8þ responses were also higher following aerosol
compared to intradermal delivery, although CD8þ responses were
comparable following the two delivery methods in BAL speci-
mens. Lastly, McShane discussed three potential approaches to
improving TB vaccine selection models: 1) developing pre-clinical
models that more closely resemble natural infection; 2) con-
ducting experimental medicine studies to better elucidate human
immunology in the target population; and 3) developing a human
mycobacterial challenge model.5. TB subunit vaccines, memory and immunity in the lung
Prof. Peter Andersen (Statens Serum Institut e SSI, Denmark)
discussed adjuvanted subunit vaccines. The rationale supporting
this vaccine approach included: 1) excellent safety proﬁles; 2) they
are molecularly well-deﬁned; 3) responses are not complicated by
immune responses targeting the vector, thereby permitting the
possibility of boosting; and 4) delivery devices allow for slow an-
tigen release. An argument against their use is their composition of
multiple antigenic components, and complex adjuvant formula-
tions, which result in challenges to GMP manufacture and analysis.
Andersen highlighted that, in both preclinical and clinical studies,
and unlike BCG, several subunit vaccines induce IL-2þTNFþ double
positive CD4þT-cells indicative of a central memory phenotype.
Andersen presented results of the evaluation of the SSI H56
vaccine in non-human primate (NHP) models. Based on analyses of
inﬂammatory markers, chest radiology, PET-CT scanning and lung
pathology, the CAF01-adjuvanted H56 vaccine appears to promote
early protection from low dose Mtb challenge with minimal pul-
monary inﬂammation/pathology and with efﬁcient control of
bacterial growth in regional lymph nodes. CAF01 and IC31, the
adjuvant systems used in the H56 vaccine in clinical development,
prevent ESAT-6 speciﬁc IFN-g responses post infection, which may
indicate an ability to prevent interferon gamma release assay
(IGRA) conversions in humans. Increasing the magnitude of the
vaccine-induced Th1 response with stronger adjuvants was found
to negatively impact efﬁcacy in the NHPs. Andersen also presented
results from human phase 1 and 2a trials of H56:IC31 and its pre-
decessor H1:IC31, demonstrating that these vaccines are well
tolerated and generate an immune proﬁle with sustained IL-2 and
TNF-alpha double positive central memory T-cells [12].6. Vaccination of adolescents in a TB endemic setting with
M72/AS01E
Dr. Adam Penn-Nicholson (SATVI, University of Cape Town,
South Africa) described results from a phase 2 safety and immu-
nogenicity trial of M72/AS01E recently conducted at SATVI in
HIV-, healthy adolescents [13]. Two doses of vaccine (n ¼ 40) or
placebo (n ¼ 20) were administered one month apart. Approxi-
mately 50% of participants were QuantiFERON (QFT)þ. M72/AS01E
demonstrated an acceptable safety proﬁle with no serious adverse
events (SAEs) reported. A marked increase in CD4þ antigen-
speciﬁc T-cell responses was seen seven days after each vaccina-
tion; responses were sustained above background throughout the
study with magnitudes among the highest from any TB vaccine
seen at SATVI. The immune response was dominated by IFN-
gamma, TNF-alpha, IL-2 triple positive cells and IFN-gamma,
TNF-alpha double positive cells. Of interest, the IL-2þTNF-alphaþ
antigen-speciﬁc CD4þ T-cells increased relatively late compared
to other T-cell populations identiﬁed. CD8þ T-cell responses were
generally detectable but low in vaccine recipients. The impor-
tance of conducting trials in TB endemic areas was highlighted by
the ﬁnding that 3 of 20 placebo recipients had signiﬁcantly higher
than background responses to M72. Also, QFTþ individuals
demonstrated rapid and sustained antigen-speciﬁc CD4þ T-cell
and antibody responses following the ﬁrst vaccination while QFT-
individuals required the second vaccination to produce similar
magnitude responses. These results suggest natural infection may
prime the immune response to M72. M72/AS01E is being further
evaluated in an ongoing multicenter phase 2b safety, immuno-
genicity and efﬁcacy trial in approximately 3500 QFTþ, HIV-
adults across Africa [3].7. DAR-901 inactivated whole cell mycobacterial booster
vaccine: phase I dose escalation study
Dr. Ford von Reyn (Geisel School of Medicine, Dartmouth Col-
lege, USA) presented the heat-inactivated, whole cell mycobacterial
vaccine candidate, DAR-901, which at the time of the Forum was
undergoing a ﬁrst-in-human, phase 1 dose escalation study in the
United States in collaboration with Aeras [14]. DAR-901 represents
a scalable, broth grown manufacturing method for agar-grown
SRL172 and is being developed as a booster for adolescents and
adults [15]. SRL172 was evaluated in Tanzania in a phase 3 trial of
2013 HIVþ, BCG þ adults who each received ﬁve vaccinations (at 0,
2, 4, 6 and 12 months). The vaccine demonstrated an acceptable
safety and tolerability proﬁle and 39% efﬁcacy against the second-
ary endpoint of preventing “deﬁnite TB” (1 positive culture or 2
positive sputum smears). Both cellular and humoral responses
were detected in this trial [16]. Von Reyn commented that a study
in the 1930s of ﬁve doses of inactivated Mycobacterium bovis,
delivered intradermally, demonstrated 42% efﬁcacy against TB
disease (p < 0.1) [17].
The ﬁrst-in-human DAR-901 phase 1 trial enrolled HIV- (n¼ 54)
andþ (n¼ 5) adults who had received BCG in the past. The double-
blind dose escalation stage of the trial administered vaccine
intradermally x3 at 0, 2 and 4 months versus saline placebo x3 or
active control (saline x2, BCG x1). Participants are followed up to 10
months. The study is designedwith dose escalation cohorts starting
at 0.1mg and escalation to 0.3 mg and 1mg. von Reyn reported that
the preliminary safety data show the vaccine has an acceptable
safety proﬁle, is well tolerated and has injection site reactions
comparable to those observed in the SRL-172 trial. Immunology
data are pending.
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Dr. Fiona Smaill (McMaster University, Canada) reported on the
development of an Ad5-vectored Ag85A vaccine. From the recom-
binant Ad5 vector, E1 and E3 have been genetically deleted, and the
expression of the Ag85A insert is driven by a CMV promoter. This
vaccine has been evaluated in several animal models including
mice, guinea pigs, goats, cattle and NHP; a ﬁrst-in-human study has
also been conducted [18]. The vaccine induced antigen speciﬁc
polyfunctional CD4þ and CD8þ T-cells (as measured by intracellular
cytokine staining) and demonstrated an acceptable safety proﬁle.
To supportaerosolvaccinationofAd5Ag85A inhumans,Smaill and
colleagues evaluated the characteristics of aerosol generated by the
Aeroneb™ Solo Single Patient Use Vibrating Mesh Nebulizer. They
found thata loadingvolumeof0.5mLcouldbedeliveredwithin2min
with about 50% of the dose available at themouth and 85%of droplets
less than 5.39 um in size, which should enhance delivery to airways
below the larynx. Vaccine viability was estimated at 17.4%. This
nebulizer system will now be used in a planned phase 1 study of
aerosol Ad5Ag85A in 36 BCGþ healthy adults [19]. Dose escalation
based on safety will be conducted using, 106, 107, and 108 pfu by
aerosol with the highest dose also delivered to a cohort intramuscu-
larly for comparison of immune responses in whole blood, PBMCs,
and BAL (by ICS and ELISpot, and for Ag85A antibodies). Induced
sputum will also be evaluated for comparison with BAL. All partici-
pantswillhavenormalpulmonary functionatbaseline;anyonewitha
history of smoking or lung disease will be excluded from the study.
Participants will be monitored for development of pulmonary
symptoms and changes in routine lung function tests.
Dr. Rhea Coler (Infectious Disease Research Institute - IDRI, USA)
was unable to present during the Forum but her planned presen-
tation of the adjuvanted subunit vaccine candidate, ID93, can be
viewed online through 2017 by visiting www.tbvaccines2015.org
and selecting the link to “Forum presentations”.
9. Conclusion
Despite progress in developing clinical TB vaccine candidates,
the current global portfolio requires greater diversity in immuno-
logic mechanisms to increase the likelihood of eventual success.
The present candidates represent rather limited immunologic
diversityemost being focused on inducing conventional CD4þ and/
or CD8þ T-cells, and/or a limited repertoire of target antigens.
Discovery efforts are now re-focusing on generating candidates
that induce a more diverse set of immunemechanisms. Other areas
of focus needed to ensure high probability of success for TB vaccine
development include standardized animal models that model
natural transmission and use clinical isolates, the development of
predeﬁned endpoints and clear criteria to deﬁne “protection”,
discovery and validation of correlates of protection and risk of
disease, new innovative trial designs such as prevention of infec-
tion and prevention of TB recurrence trials, and a safe and sensitive
human challenge model. Each of these, once validated as predictive
with human efﬁcacy data, would transform the process of future TB
vaccine development.
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